Price
$0.6728
Decreased by -1.45%
Dollar Volume
102.02 K
ADR%
9.37
Earnings Report Date (estimate)
Mar 28, 23 (-0.21)
Market Cap.
20.26 M
Shares Float
20.46 M
Shares Outstanding
30.11 M
Beta
0.00
Price / Earnings
-0.63
BPR
5.35
20D Range
0.59 1.02
50D Range
0.59 1.02
200D Range
0.59 2.04
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 17, 22 -0.30
Decreased by -151.72%
-0.36
Increased by +16.67%
Nov 14, 22 -0.30
Increased by +43.40%
-0.36
Increased by +16.67%
Aug 15, 22 -0.30
Increased by +48.28%
-0.46
Increased by +34.78%
May 16, 22 -0.48
Increased by +69.23%
-0.43
Decreased by -11.63%
Mar 30, 22 0.58
Increased by +130.53%
-0.62
Increased by +193.55%
Nov 12, 21 -0.53 -0.72
Increased by +26.39%
Aug 12, 21 -0.58 -0.69
Increased by +15.94%
May 17, 21 -1.56 -0.62
Decreased by -151.61%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by -100.00%
-8.99 M
Increased by +42.77%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 653.00 K
Increased by +20.93%
-9.14 M
Increased by +46.47%
Decreased by -1.40 K%
Increased by +55.73%
Mar 31, 22 1.65 M
Increased by +344.20%
-14.24 M
Increased by +61.19%
Decreased by -864.08%
Increased by +91.26%
Dec 31, 21 25.94 M
Increased by +5.55 K%
14.89 M
Increased by +151.57%
Increased by +57.40%
Increased by +100.91%
Sep 30, 21 1.46 M
Increased by +76.54%
-15.70 M
Increased by +11.12%
Decreased by -1.08 K%
Increased by +49.66%
Jun 30, 21 540.00 K
Decreased by -25.93%
-17.07 M
Increased by +16.07%
Decreased by -3.16 K%
Decreased by -13.30%
Mar 31, 21 371.00 K
Decreased by -57.11%
-36.69 M
Decreased by -177.47%
Decreased by -9.89 K%
Decreased by -546.93%
Dec 31, 20 459.00 K
Decreased by -34.05%
-28.88 M
Decreased by -80.30%
Decreased by -6.29 K%
Decreased by -173.40%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.